Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Wells A. Messersmith et al.|Annals of Oncology|2021Cited by 371
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.Edward M. Schaeffer, Deborah A. Freedman-Cass, James A. Eastham et al.|PubMed|2022Cited by 172
Reversible epigenetic alterations regulate class I HLA loss in prostate cancerTamara S. Rodems, Joshua M. Lang|Communications Biology|2022Cited by 52
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M. Sperger, Joshua M. Lang|Clinical Cancer Research|2023Cited by 52
Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signalingErika Héninger, Joshua M. Lang|Medical Oncology|2021Cited by 20